CPhI WW 2013 – The best yet
CPhI Worldwide returned to the Frankfurt Messe last week, for yet another successful congregation of business and innovation in the global pharmaceutical industry. With more than 30,000 attendees and over 2,200 exhibitors from more than 140 countries, CPhI WW 2013 was one of the best attended in the history of the show.
The introduction and application of biocatalysis technology for more cost-effective and sustainable API development and manufacturing has been a recurrent topic at the exhibition in recent years. The industry’s progression towards green chemistry was reflected in presentations from Innovation Award nominees and in the Speakers Corner seminars across the three days. Codexis, a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, was in particular acknowledged by the CPhI Pharma Innovation Awards for its innovative development of enzymes for green and scalable biocatalytic oxidations. Codexis’ forward-thinking was also pinpointed along the venue’s walkways, where its novel use of the event floors created real standout from the crowds.
Focus was also on the growth of Indian pharma, with CPhI’s online communityPharma Evolution conducting a number of interviews with key representatives of the Indian government, industry and the India Brand Equity Foundation (IBEF). Amongst the interviews, Dr. R. Ananthanaryanan, President, Dr. Reddy’s Laboratories Ltd., talked about the country’s strength in APIs and its growing presence in finished formulations. CPhI’s survey on formulation indicated that India is the primary source of most APIs (Cited: Show Daily, Wednesday 23 October). Globally, India ranks among the top exporters of formulations in volume. This growth has been shaped by the conducive environment created by India’s government to ensure that growth and quality match with its CPhI motto, which was: “Credible, Affordable, and Sustainable.”
Other companies reacting to the changing market place are Cambridge Major Laboratories and AAI Pharma. At the beginning of this month the two organisations announced plans to join forces. The merger, which was finalized today, will offer a full suite of integrated CMC services that will deliver meaningful value to customers and the ability to execute with equal strength. Their presence at CPhI sparked interest regarding the strategic rationale and immediate benefits that will arise of this unique service offering.
With the Turkish pharmaceutical market forecast to grow by $16 billion by 2014, CPhI announced that the Eurasian region is the latest to be added to its series of global events. The launch of CPhI Istanbul recognises Istanbul’s strategic geographical positioning to both Europe and Asia and the potential that the city has to become a foremost provider of pharmaceuticals.
Another trend that is growing throughout the pharmaceutical industry is the use of social media. Attendees took to the digital arena to stay well connected before, during and after the show. Some of the best Twitter interactions from the industry’s movers and shakers were rounded up by in-Pharma Technologist’s account of ‘Frankfurt becomes Phrankfurt’ and CHEManager Europe (@CHEManager_EU) was prized for excellent use of Twitter at the event. There was a buzz around social networks that are providing a new route for sharing information without impacting on IP.
CPhI Worldwide 2014 will be taking place in Paris in just over 48 weeks (7-9 October).